JCM
ALXN

Jacobi Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Jacobi Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-326
Closed -$60K – 1519
2021
Q2 		$60K Sell
326
-2,780
-90% -$477K 0.01% 589
2021
Q1 		$475K Sell
3,106
-100
-3% -$15.5K 0.07% 227
2020
Q4 		$501K Sell
3,206
-214
-6% -$27.5K 0.08% 200
2020
Q3 		$391K Sell
3,420
-74
-2% -$7.98K 0.07% 221
2020
Q2 		$392K Buy
3,494
+150
+4% +$15.9K 0.07% 204
2020
Q1 		$300K Sell
3,344
-413
-11% -$40.5K 0.06% 212
2019
Q4 		$406K Sell
3,757
-171
-4% -$18.3K 0.07% 208
2019
Q3 		$385K Buy
3,928
+3,850
+4,936% +$434K 0.08% 204
2019
Q2 		$10K Hold
78
– – ﹤0.01% 742
2019
Q1 		$11K Hold
78
– – ﹤0.01% 693
2018
Q4 		$8K Hold
78
– – ﹤0.01% 700
2018
Q3 		$11K Hold
78
– – ﹤0.01% 697
2018
Q2 		$10K Hold
78
– – ﹤0.01% 717
2018
Q1 		$8K Hold
78
– – ﹤0.01% 735
2017
Q4 		$9K Hold
78
– – ﹤0.01% 689
2017
Q3 		$11K Sell
78
-9
-10% -$1.22K ﹤0.01% 631
2017
Q2 		$11K Hold
87
– – ﹤0.01% 560
2017
Q1 		$10K Buy
87
+9
+12% +$1.16K 0.01% 470
2016
Q4 		$11K Sell
78
-9
-10% -$1.1K 0.01% 419
2016
Q3 		$11K Buy
87
+78
+867% +$10K 0.01% 466
2016
Q2 		$1K Buy
+9
New +$1.28K ﹤0.01% 700

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Jacobi Capital Management's ALXN Position: Q3 2021 in Review

Jacobi Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 326 shares — an estimated $60K sold.

Jacobi Capital Management first reported a position in ALXN in Q2 2016 and held it in 21 quarters. The position peaked at $501K in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Jacobi Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Jacobi Capital Management sold 326 Alexion Pharmaceuticals shares in Q3 2021, an estimated $60K.
  • Jacobi Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 21 quarters.
  • Jacobi Capital Management's Alexion Pharmaceuticals position peaked at $501K in Q4 2020.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Jacobi Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.